The FDA has issued warning letters to five online peptide vendors for marketing unapproved retatrutide and other peptide products, with a September 8 response deadline now days away. The letters, dated August 24 and posted on FDA.gov on September 1, name Peak Performance Peptides, Royal Peptides LLC, NuScience Peptides LLC, Peptide Partners LLC, and Tex Peptides. This is the same August 24 batch previously reported, not a separate new sweep.
The enforcement action coincides with Eli Lilly’s expanding legal fight against compounders and online sellers of retatrutide, an investigational drug that has not received FDA approval. The dual track of federal warning letters and private litigation signals intensifying pressure on the gray-market peptide trade.
What happened
The FDA warning letters cite the five companies for distributing unapproved peptide products, including retatrutide, semaglutide, tirzepatide, and other compounds. The agency’s letter to Royal Peptides LLC, publicly posted on the FDA website, identifies the sale and distribution of unapproved new drug products.
Recipients of FDA warning letters typically have 15 working days to respond with a description of corrective actions. The September 8 deadline reflects that window from the August 24 letter date. Companies that fail to respond or that continue selling the cited products face potential escalation, including injunctions, product seizures, or referral to the U.S. Department of Justice.
Why it matters
The FDA letters and Eli Lilly’s separate lawsuits against online peptide sellers represent converging federal and industry enforcement against the unapproved retatrutide market. Retatrutide has not been approved by the FDA for any use and remains an investigational compound.
The enforcement sweep touches a wide range of stakeholders: online peptide vendors, compounding pharmacies operating under Sections 503A and 503B, telehealth platforms offering peptide products, payment processors, and consumers. For consumers purchasing peptides outside approved drug channels, the warnings underscore ongoing regulatory uncertainty about product quality, labeling accuracy, and legal status.
What to watch next
- Whether the five named companies submit responses by the September 8 deadline
- Whether the FDA pursues injunctions, seizures, or DOJ referrals against non-compliant vendors
- The direction of Eli Lilly’s parallel litigation against peptide sellers and compounders
- Whether additional FDA warning letters target other vendors in the online peptide market
Sources
- InsideHealthPolicy.com — FDA steps up retatrutide enforcement against online peptide sellers following Eli Lilly suit
- FDA Warning Letters — Royal Peptides LLC
Industry information only. Not medical or legal advice.
